The IL1RN Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human A-549 lung adenocarcinoma cell line. This product provides a pooled population of cells harboring targeted disruption of the IL1RN gene, which encodes the interleukin-1 receptor antagonist (IL-1Ra). The polyclonal format offers a heterogeneous mixture of edited alleles generated by non-homologous end joining following Cas9-mediated double-strand breaks, enabling loss-of-function studies without the need for single-cell cloning. These cells serve as a versatile tool for investigating IL-1 signaling in a lung cancer background.
The parental A-549 cell line, established from a 58-year-old male patient with lung adenocarcinoma, is a widely employed in vitro model in cancer biology, respiratory toxicology, and drug screening. A-549 cells exhibit epithelial morphology and retain key characteristics of alveolar type II pneumocytes, making them suitable for studying lung tumorigenesis and the tumor microenvironment. Their robust growth and well-characterized signaling network facilitate reproducible experiments in inflammatory and oncogenic contexts. As an adherent line with high transfection efficiency, A-549 cells are amenable to downstream assays including reporter gene analyses, immunoblotting, and cytokine profiling.
IL1RN encodes the interleukin-1 receptor antagonist (IL-1Ra), an endogenous inhibitor of IL-1?? and IL-1?? signaling. IL-1Ra competitively binds IL1R1 and IL1R2 without recruiting IL1RAP, preventing formation of the active receptor complex. This blockade suppresses IL-1-induced activation of the NF-??B pathway, including phosphorylation of NFKBIA and nuclear translocation of RELA, and the MAPK cascade involving MAPK8 (JNK). Consequently, expression of downstream targets such as IL6, CXCL8, MMP1, and PTGS2 is reduced. Upstream regulators of IL1RN include TNF, IL1B, and NFKB1, forming feedback loops that modulate inflammatory responses. IL1RN also directly interferes with recruitment of the adaptors MYD88, IRAK4, and IRAK1 to the receptor, thus disrupting signal propagation.
In the A-549 lung adenocarcinoma background, disruption of IL1RN potentiates IL-1-mediated inflammatory signaling, providing a pertinent model for studying tumor-associated inflammation. Lung adenocarcinoma cells frequently reside in an inflammatory microenvironment where IL-1 signaling contributes to tumor progression, immune evasion, and chemoresistance. By removing the endogenous antagonist, these knockout cells allow researchers to dissect the specific contribution of IL-1Ra to tumor cell-intrinsic signaling and cross-talk with stromal components. This model is particularly valuable for exploring the role of IL-1 signaling in epithelial-mesenchymal transition, cytokine production, and NF-??B-driven transcriptional programs that are often dysregulated in lung cancer.
These IL1RN knockout polyclonal cells enable functional studies including western blotting for phospho-NF-??B and phospho-JNK, ELISA measurement of IL-6 and CXCL8, and RT-qPCR analysis of target genes. They are suitable for NF-??B luciferase reporter assays and high-throughput screening of IL-1 pathway modulators. Additional applications include co-culture experiments to study tumor-immune interactions and modeling of inflammatory diseases like rheumatoid arthritis and DIRA in a lung epithelial context. For technical details or custom projects, contact Ascent Research.
